PubMed Health⌕ Search

Biomedical subjects

K Sampi

Publications and source records attributed to K Sampi.

95 records · Page 6Linked to original sources
PubMedDate not supplied

A phase II study of epirubicin in acute leukemia: a cooperative group study.

A new doxorubicin analogue, epirubicin (EPI), was evaluated in 41 patients with acute leukemia at 11 Japanese institutions participating in a phase II study between January 1983 and July 1985; during this period 35 patients were considered evaluable. There were 25 males and 10 females with a median age of 43 years (range, 19-71 years) and the median PS of 2 (range, 0-4). EPI was given to 25 patients who had previously been treated with intensive combination chemotherapy, of whom 22 had already received anthracyclines. Ten patients had not been treated previously. Two dose schedules were explored. The higher dose schedule (18 cases) consisted of the administration of 24 to 60 mg/m2 for 3 to 5 consecutive days, and the lower dose schedule (17 cases) consisted of 11 to 20 mg/m2 for 5 to 7 days. Remissions were obtained in 7 patients (20%), 2 of whom showed complete remission and 5 partial remission. The remission duration was 2, 2, 3, 5, 16, 16 and 29+ weeks, respectively. The expected myelosuppression was universal. Stomatitis occurred in 15 patients, of which 7 cases were severe. This stomatitis occurred frequently in the higher dose schedule, and was thought to be a dose-limiting factor. In others, alopecia, G.I. symptoms, and diarrhoea (4 patients) were seen. These results from a cooperative group study indicated that EPI was an effective drug for the treatment of acute leukemia.

Acute Disease↗
PubMedDate not supplied

Treatment of acute non-lymphocytic leukemia in Saitama Cancer Center.

Forty patients with previously untreated acute nonlymphocytic leukemia (ANLL) were treated at Saitama Cancer Center between February 1979 and November 1983. Their median age was 43 years (range: 14 to 68 years), 13 patients (32.5%) being 55 years old or older. Twenty-three patients had Auer bodies. Complete remission was achieved in 75.0% of the patients (30/40) with the first line therapy, and in 6 of 7 patients in the second line therapy. Thus, the overall remission rate was 90.0%. The median duration of remission was 14 months and 39% of the patients showed no relapse within 3 years. The median survival for all patients was 26 months and the actuarial 3-year survival rate was 41%. The better results in this series were thought to be due to intensive post-induction reinforcement therapy.

Aclarubicin↗